Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Applied DNA Sciences Inc APDN

Technology Scientific & Technical Instruments
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic... see more

Recent & Breaking News (NDAQ:APDN)

Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

Accesswire October 30, 2024

Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16

Accesswire October 15, 2024

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Accesswire September 18, 2024

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Accesswire September 17, 2024

Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Accesswire September 17, 2024

Applied DNA Launches Mpox Clade I and Clade II Testing Service

Accesswire September 11, 2024

Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Accesswire September 4, 2024

Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Accesswire August 23, 2024

Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Accesswire August 19, 2024

Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

Accesswire August 8, 2024

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

Accesswire August 7, 2024

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

Accesswire July 29, 2024

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit

Accesswire July 29, 2024

Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability

Accesswire July 25, 2024

U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract

Accesswire July 18, 2024

Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

Accesswire June 20, 2024

Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing

Accesswire June 18, 2024

Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Accesswire June 13, 2024

Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform

Accesswire June 5, 2024

Applied DNA Announces Pricing of $12 Million Public Offering

Accesswire May 28, 2024